hydrazinocurcumin: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
hydrazinocurcumin : A pyrazole obtained by cyclocodensation of the two carbonyl groups of curcumin with hydrazine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 135494223 |
| CHEMBL ID | 180239 |
| CHEBI ID | 84340 |
| MeSH ID | M0451973 |
| Synonym |
|---|
| (e)-3,5-bis[beta-(4-hydroxy-3-methoxyphenyl)-ethenyl]-1h-pyrazole |
| 4,40-(1e,10e)-2,20-(1-h-pyrazole-3,5-diyl)bis(ethene-2,1-diyl)bis(2-methoxyphenol) |
| 4,4''-2,2''-(1h-pyrazole-3,5-diyl)bis(ethene-2,1-diyl)bis(2-methoxyphenol) |
| 4-((e)-2-{3-[(e)-2-(4-hydroxy-3-methoxyphenyl)vinyl]-1h-pyrazol-5-yl}vinyl)-2-methoxyphenol |
| bdbm50163748 |
| 4-(2-(5-(4-hydroxy-3-methoxystyryl)-1h-pyrazol-3-yl)vinyl)-2-methoxyphenol |
| CHEMBL180239 , |
| curcumin pyrazole |
| chebi:84340 , |
| 4-[(e)-2-[3-[(e)-2-(4-hydroxy-3-methoxy-phenyl)vinyl]-1h-pyrazol-5-yl]vinyl]-2-methoxy-phenol |
| 4,4'-[1h-pyrazole-3,5-diyldi(e)ethene-2,1-diyl]bis(2-methoxyphenol) |
| hydrazinocurcumin |
| pyrazole-curcumin |
| Q27157689 |
| 4,4'-((1e,1'e)-(1h-pyrazole-3,5-diyl)bis(ethene-2,1-diyl))bis(2-methoxyphenol) |
| 131068-23-0 |
Hydrazinocurcumin is a semi-synthetic analogue of curcumin with superior anticancer and anti-angiogenic activities.
| Excerpt | Reference |
|---|---|
| "Hydrazinocurcumin is a semi-synthetic analogue of curcumin with superior anticancer and anti-angiogenic activities. " | ( Development and validation of bioanalytical method for the determination of hydrazinocurcumin in rat plasma and organs by HPLC-UV. Attimarad, M; Gupta, S; Nair, AB, 2020) |
| "Hydrazinocurcumin (HZC) is a patented multiactivity compound and is a potent derivative of curcumin which is not yet explored for further development as formulation and requires the determination of biopharmaceutical suitability of the molecule. " | ( Simultaneous determination of hydrazinocurcumin and phenol red in samples from rat intestinal permeability studies: HPLC method development and validation. Jachak, SM; Jain, JP; Kumar, N; Rathore, R; Srivastava, A, 2008) |
| Excerpt | Reference |
|---|---|
| " The present study aimed to evaluate the unexplored pharmacokinetic profile of this agent in experimental rats." | ( Pharmacokinetics and tissue distribution of hydrazinocurcumin in rats. Choudhury, H; Dhanawat, M; Gupta, S; Jacob, S; Munjal, K; Nair, AB, 2021) |
| " Blood samples were collected at different pre-determined time intervals to determine the pharmacokinetic parameters." | ( Pharmacokinetics and tissue distribution of hydrazinocurcumin in rats. Choudhury, H; Dhanawat, M; Gupta, S; Jacob, S; Munjal, K; Nair, AB, 2021) |
| " The obtained data from the pharmacokinetic study indicated that HZC was instantaneously distributed and moderately eliminated from body fluids." | ( Pharmacokinetics and tissue distribution of hydrazinocurcumin in rats. Choudhury, H; Dhanawat, M; Gupta, S; Jacob, S; Munjal, K; Nair, AB, 2021) |
| Excerpt | Reference |
|---|---|
| " In this paper, structural modifications of curcumin scaffold were examined in order to improve its bioavailability and stability in physiological conditions, as well as its ability to interfere with β-amyloid fibrils and aggregates." | ( Curcumin derivatives and Aβ-fibrillar aggregates: An interactions' study for diagnostic/therapeutic purposes in neurodegenerative diseases. Asti, M; Basile, V; Bednarikova, Z; Ferrari, E; Gazova, Z; Imbriano, C; Menziani, MC; Orteca, G; Rigamonti, L; Rigillo, G; Saladini, M; Tavanti, F, 2018) |
| " However, the poor stability, solubility, in vivo bioavailability and weak activity of CU greatly limit its clinical application." | ( Recent advances of analogues of curcumin for treatment of cancer. Pi, C; Wei, Y; Ye, Y; Zhao, L; Zhao, S, 2019) |
| "Curcumin, a natural polyphenol from Curcuma longa, is known to possess diversified pharmacological roles including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic properties; however, its bioavailability is severely limited due to its poor solubility, poor absorption, rapid metabolism, and significant elimination." | ( Pharmacokinetics and tissue distribution of hydrazinocurcumin in rats. Choudhury, H; Dhanawat, M; Gupta, S; Jacob, S; Munjal, K; Nair, AB, 2021) |
| " These results revealed a faster rate and longer duration of absorption with intraperitoneal administration, which further resulted in enhanced absolute bioavailability of HZC (29." | ( Pharmacokinetics and tissue distribution of hydrazinocurcumin in rats. Choudhury, H; Dhanawat, M; Gupta, S; Jacob, S; Munjal, K; Nair, AB, 2021) |
| Role | Description |
|---|---|
| EC 2.3.1.48 (histone acetyltransferase) inhibitor | An EC 2.3.1.* (acyltransferase transferring other than amino-acyl group) inhibitor that interferes with the function of histone acetyltransferase (EC 2.3.1.48). |
| antineoplastic agent | A substance that inhibits or prevents the proliferation of neoplasms. |
| EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor | An EC 2.7.11.* (protein-serine/threonine kinase) inhibitor that interferes with the action of non-specific serine/threonine protein kinase (EC 2.7.11.1), a kinase enzyme involved in phosphorylation of hydroxy group of serine or threonine. |
| angiogenesis modulating agent | An agent that modulates the physiologic angiogenesis process. This is accomplished by endogenous angiogenic proteins and a variety of other chemicals and pharmaceutical agents. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| pyrazoles | |
| polyphenol | Members of the class of phenols that contain 2 or more benzene rings each of which is substituted by at least one hydroxy group. |
| aromatic ether | Any ether in which the oxygen is attached to at least one aryl substituent. |
| olefinic compound | Any organic molecular entity that contains at least one C=C bond. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Amyloid-beta precursor protein | Homo sapiens (human) | IC50 (µMol) | 6.2920 | 0.0005 | 3.8895 | 10.0000 | AID1894193; AID1894195; AID1894196 |
| Polyunsaturated fatty acid 5-lipoxygenase | Homo sapiens (human) | IC50 (µMol) | 0.1618 | 0.0001 | 1.6847 | 9.3200 | AID1155573; AID1155574; AID1155590; AID1155591; AID1155592 |
| Microtubule-associated protein tau | Homo sapiens (human) | IC50 (µMol) | 34.0000 | 0.0690 | 1.9769 | 3.5000 | AID1894197 |
| Matrix metalloproteinase-9 | Homo sapiens (human) | IC50 (µMol) | 19.4000 | 0.0000 | 0.7053 | 10.0000 | AID368021 |
| Polyunsaturated fatty acid lipoxygenase ALOX12 | Homo sapiens (human) | IC50 (µMol) | 7.3000 | 0.1000 | 2.4523 | 10.0000 | AID1155583 |
| Nuclear factor NF-kappa-B p105 subunit | Homo sapiens (human) | IC50 (µMol) | 29.8000 | 0.0001 | 1.9731 | 8.0000 | AID1155585 |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | IC50 (µMol) | 9.7000 | 0.0007 | 0.9774 | 9.7000 | AID247571 |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | IC50 (µMol) | 9.7000 | 0.0001 | 0.9950 | 10.0000 | AID247571 |
| Alpha-synuclein | Homo sapiens (human) | IC50 (µMol) | 126.8000 | 0.1900 | 3.8204 | 9.8000 | AID1695732 |
| Signal transducer and activator of transcription 3 | Homo sapiens (human) | IC50 (µMol) | 16.2000 | 0.0230 | 4.1378 | 9.9800 | AID1155586 |
| Nuclear factor NF-kappa-B p100 subunit | Homo sapiens (human) | IC50 (µMol) | 29.8000 | 0.0001 | 1.8088 | 8.0000 | AID1155585 |
| Transcription factor p65 | Homo sapiens (human) | IC50 (µMol) | 29.8000 | 0.0001 | 1.8981 | 8.8000 | AID1155585 |
| Calcium/calmodulin-dependent protein kinase type II subunit alpha | Homo sapiens (human) | IC50 (µMol) | 3.6450 | 0.0000 | 1.6395 | 10.0000 | AID687449; AID687450; AID687451; AID687453 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Protein kinase C epsilon type | Homo sapiens (human) | EC50 (µMol) | 18.8100 | 0.0095 | 2.9484 | 8.1900 | AID630078 |
| Protein kinase C theta type | Homo sapiens (human) | EC50 (µMol) | 7.2500 | 0.0095 | 2.7787 | 7.2500 | AID630079 |
| Protein kinase C delta type | Homo sapiens (human) | EC50 (µMol) | 14.9700 | 0.0041 | 0.9229 | 5.1700 | AID630077 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Amyloid-beta precursor protein | Homo sapiens (human) | DC50 | 1.4700 | 0.7300 | 0.9933 | 1.4700 | AID1398101 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1511093 | Cytotoxicity against human WRO cells at 10 uM after 72 hrs by MTS assay relative to control | 2019 | European journal of medicinal chemistry, Oct-15, Volume: 180 | Recent advances of analogues of curcumin for treatment of cancer. |
| AID410461 | Antiproliferative activity against human MCF7 cells after 72 hrs by MTS-PMS assay | 2009 | Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1 | Synthesis and evaluation of electron-rich curcumin analogues. |
| AID687451 | Inhibition of autophosphorylated alphaCaMK2 using GST-NR2A as substrate incubated for 1 min prior to substrate addition measured after 1 min | 2012 | Bioorganic & medicinal chemistry, Oct-15, Volume: 20, Issue:20 | Curcumin is an inhibitor of calcium/calmodulin dependent protein kinase II. |
| AID1894196 | Inhibition of amyloid beta 42 secretion transfected in human H4 cells incubated for 20 to 24 hrs by LPECL assay | 2021 | European journal of medicinal chemistry, Mar-15, Volume: 214 | Amyloid-β and tau aggregation dual-inhibitors: A synthetic and structure-activity relationship focused review. |
| AID1155578 | Inhibition of COX1-mediated PGE2 production in human platelets assessed as residual activity by measuring formation of 12-HHT from arachidonic acid preincubated at 10 uM for 5 mins measured after 5 mins by RP-HPLC analysis relative to control | 2014 | Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13 | SAR studies on curcumin's pro-inflammatory targets: discovery of prenylated pyrazolocurcuminoids as potent and selective novel inhibitors of 5-lipoxygenase. |
| AID247571 | Anti-oxidant activity in DPPH radicak scavenging assay; n=3-4 | 2005 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 15, Issue:7 | Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cyclooxygenase inhibitory and anti-inflammatory agents. |
| AID687445 | Inhibition of Albino Wistar rat CaMK2 in brain cytosolic fraction using GST-NR2A as substrate incubated for 1 min prior to substrate addition measured after 1 min in presence of EGTA | 2012 | Bioorganic & medicinal chemistry, Oct-15, Volume: 20, Issue:20 | Curcumin is an inhibitor of calcium/calmodulin dependent protein kinase II. |
| AID418007 | Ratio of IC50 for human MCF10A cells to IC50 for human MCF7 cells | 2009 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7 | Structure-activity relationship studies of curcumin analogues. |
| AID687455 | Inhibition of Albino Wistar rat CaMK2 autophosphorylation at Thr286 in postsynaptic density fraction using [gamma32P]ATP incubated for 30 secs prior to ATP addition measured after 30 secs | 2012 | Bioorganic & medicinal chemistry, Oct-15, Volume: 20, Issue:20 | Curcumin is an inhibitor of calcium/calmodulin dependent protein kinase II. |
| AID1175313 | Aqueous solubility of the compound after 12 hrs by shake-flask method | 2014 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 24, Issue:24 | Structure activity relationship study of curcumin analogues toward the amyloid-beta aggregation inhibitor. |
| AID323180 | Antimalarial activity against chloroquine-sensitive Plasmodium falciparum FCK2 | 2008 | Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6 | Synthesis and exploration of novel curcumin analogues as anti-malarial agents. |
| AID630078 | Binding affinity to PKCepsilon C1B subdomain after 1 hr by fluorescence quenching analysis | 2011 | Bioorganic & medicinal chemistry, Nov-01, Volume: 19, Issue:21 | Binding of isoxazole and pyrazole derivatives of curcumin with the activator binding domain of novel protein kinase C. |
| AID417999 | Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay | 2009 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7 | Structure-activity relationship studies of curcumin analogues. |
| AID418001 | Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay | 2009 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7 | Structure-activity relationship studies of curcumin analogues. |
| AID1155598 | Inhibition of COX1-mediated PGD2 formation in LPS-stimulated human monocytes preincubated for 15 mins before arachidonic acid substrate addition measured after 30 mins by UPLC-MS/MS analysis | 2014 | Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13 | SAR studies on curcumin's pro-inflammatory targets: discovery of prenylated pyrazolocurcuminoids as potent and selective novel inhibitors of 5-lipoxygenase. |
| AID1155583 | Inhibition of 12-LO in human neutrophils | 2014 | Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13 | SAR studies on curcumin's pro-inflammatory targets: discovery of prenylated pyrazolocurcuminoids as potent and selective novel inhibitors of 5-lipoxygenase. |
| AID1155593 | Ratio of curcumin IC50 to compound IC50 for 5-LO-mediated LTB4 formation in LPS-stimulated human monocytes preincubated for 15 mins before arachidonic acid substrate addition measured after 30 mins by UPLC-MS/MS analysis | 2014 | Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13 | SAR studies on curcumin's pro-inflammatory targets: discovery of prenylated pyrazolocurcuminoids as potent and selective novel inhibitors of 5-lipoxygenase. |
| AID1155590 | Inhibition of 5-LO-mediated LTB4 formation in LPS-stimulated human monocytes preincubated for 15 mins before arachidonic acid substrate addition measured after 30 mins by UPLC-MS/MS analysis | 2014 | Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13 | SAR studies on curcumin's pro-inflammatory targets: discovery of prenylated pyrazolocurcuminoids as potent and selective novel inhibitors of 5-lipoxygenase. |
| AID1155592 | Inhibition of 5-LO-mediated 5,12-DiHETE formation in LPS-stimulated human monocytes preincubated for 15 mins before arachidonic acid substrate addition measured after 30 mins by UPLC-MS/MS analysis | 2014 | Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13 | SAR studies on curcumin's pro-inflammatory targets: discovery of prenylated pyrazolocurcuminoids as potent and selective novel inhibitors of 5-lipoxygenase. |
| AID1398101 | Disruption of recombinant human amyloid beta (1 to 40) fibrils after 24 hrs by ThT fluorescence assay | 2018 | Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14 | Curcumin derivatives and Aβ-fibrillar aggregates: An interactions' study for diagnostic/therapeutic purposes in neurodegenerative diseases. |
| AID1155572 | Inhibition of mPGES1-mediated PGE2 production in microsomes of IL-1beta stimulated human A549 cells assessed as residual activity preincubated at 10 uM for 15 mins by RP-HPLC analysis relative to control | 2014 | Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13 | SAR studies on curcumin's pro-inflammatory targets: discovery of prenylated pyrazolocurcuminoids as potent and selective novel inhibitors of 5-lipoxygenase. |
| AID368021 | Reduction of MMP9 activity in TNF-alpha/IL1-beta-stimulated human Caco-2 cells treated 1 hr before stimulation by zymography | 2009 | Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3 | Synthesis and biological evaluation of curcuminoid pyrazoles as new therapeutic agents in inflammatory bowel disease: effect on matrix metalloproteinases. |
| AID418002 | Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay | 2009 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7 | Structure-activity relationship studies of curcumin analogues. |
| AID368020 | Reduction of MMP9 activity in TNF-alpha/IL1-beta-stimulated human Caco-2 cells at 50 uM treated 1 hr before stimulation by zymography | 2009 | Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3 | Synthesis and biological evaluation of curcuminoid pyrazoles as new therapeutic agents in inflammatory bowel disease: effect on matrix metalloproteinases. |
| AID1155600 | Inhibition of COX2-mediated PGF2alpha formation in LPS-stimulated human monocytes preincubated for 15 mins before arachidonic acid substrate addition measured after 30 mins by UPLC-MS/MS analysis | 2014 | Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13 | SAR studies on curcumin's pro-inflammatory targets: discovery of prenylated pyrazolocurcuminoids as potent and selective novel inhibitors of 5-lipoxygenase. |
| AID418005 | Ratio of IC50 for human MCF10A cells to IC50 for human PC3 cells | 2009 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7 | Structure-activity relationship studies of curcumin analogues. |
| AID630077 | Binding affinity to PKCdelta C1B subdomain after 1 hr by fluorescence quenching analysis | 2011 | Bioorganic & medicinal chemistry, Nov-01, Volume: 19, Issue:21 | Binding of isoxazole and pyrazole derivatives of curcumin with the activator binding domain of novel protein kinase C. |
| AID1155576 | Antioxidant activity assessed as DPPH free radical scavenging activity at 10 uM after 30 mins by UPLC-MS/MS analysis by spectrophotometric analysis | 2014 | Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13 | SAR studies on curcumin's pro-inflammatory targets: discovery of prenylated pyrazolocurcuminoids as potent and selective novel inhibitors of 5-lipoxygenase. |
| AID617276 | Inhibition of goat brain tubulin polymerization assessed as turbidity by UV spectrophotometry | 2011 | Journal of medicinal chemistry, Sep-22, Volume: 54, Issue:18 | Curcumin recognizes a unique binding site of tubulin. |
| AID687396 | Inhibition of Albino Wistar rat CaMK2 autophosphorylation at Thr286 in brain cytosolic fraction using [gamma32P]ATP incubated for 30 secs prior to ATP addition measured after 30 secs | 2012 | Bioorganic & medicinal chemistry, Oct-15, Volume: 20, Issue:20 | Curcumin is an inhibitor of calcium/calmodulin dependent protein kinase II. |
| AID243603 | Anti-inflammatory activity in rat paw edema assay at 75 mg/kg | 2005 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 15, Issue:7 | Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cyclooxygenase inhibitory and anti-inflammatory agents. |
| AID1894195 | Inhibition of amyloid beta 40 secretion transfected in human H4 cells incubated for 20 to 24 hrs by LPECL assay | 2021 | European journal of medicinal chemistry, Mar-15, Volume: 214 | Amyloid-β and tau aggregation dual-inhibitors: A synthetic and structure-activity relationship focused review. |
| AID418000 | Antiproliferative activity against human LNCAP cells after 72 hrs by MTT assay | 2009 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7 | Structure-activity relationship studies of curcumin analogues. |
| AID1155601 | Inhibition of COX2-mediated PGD2 formation in LPS-stimulated human monocytes preincubated for 15 mins before arachidonic acid substrate addition measured after 30 mins by UPLC-MS/MS analysis | 2014 | Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13 | SAR studies on curcumin's pro-inflammatory targets: discovery of prenylated pyrazolocurcuminoids as potent and selective novel inhibitors of 5-lipoxygenase. |
| AID410462 | Antiproliferative activity against human SKBR3 cells after 72 hrs by MTS-PMS assay | 2009 | Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1 | Synthesis and evaluation of electron-rich curcumin analogues. |
| AID1894198 | Inhibition of tau depolymerization (unknown origin) transfected in H4 cells incubated for 20 to 24 hrs by LPECL assay | 2021 | European journal of medicinal chemistry, Mar-15, Volume: 214 | Amyloid-β and tau aggregation dual-inhibitors: A synthetic and structure-activity relationship focused review. |
| AID687449 | Inhibition of alphaCaMK2 autophosphorylation at Thr286 using [gamma32P]ATP incubated for 30 secs prior to ATP addition measured after 30 secs | 2012 | Bioorganic & medicinal chemistry, Oct-15, Volume: 20, Issue:20 | Curcumin is an inhibitor of calcium/calmodulin dependent protein kinase II. |
| AID630079 | Binding affinity to PKCtheta C1B subdomain after 1 hr by fluorescence quenching analysis | 2011 | Bioorganic & medicinal chemistry, Nov-01, Volume: 19, Issue:21 | Binding of isoxazole and pyrazole derivatives of curcumin with the activator binding domain of novel protein kinase C. |
| AID1155597 | Inhibition of COX1-mediated PGF2alpha formation in LPS-stimulated human monocytes preincubated for 15 mins before arachidonic acid substrate addition measured after 30 mins by UPLC-MS/MS analysis | 2014 | Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13 | SAR studies on curcumin's pro-inflammatory targets: discovery of prenylated pyrazolocurcuminoids as potent and selective novel inhibitors of 5-lipoxygenase. |
| AID1155596 | Inhibition of mPGES1-mediated PGE2 formation in LPS-stimulated human monocytes preincubated for 15 mins before arachidonic acid substrate addition measured after 30 mins by UPLC-MS/MS analysis | 2014 | Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13 | SAR studies on curcumin's pro-inflammatory targets: discovery of prenylated pyrazolocurcuminoids as potent and selective novel inhibitors of 5-lipoxygenase. |
| AID1398102 | Disruption of recombinant human amyloid beta (1 to 40) fibrils after 2 hrs by ThT fluorescence assay | 2018 | Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14 | Curcumin derivatives and Aβ-fibrillar aggregates: An interactions' study for diagnostic/therapeutic purposes in neurodegenerative diseases. |
| AID1155586 | Inhibition of STAT3 transcriptional activity in human HaCaT cells after 6 hrs by luciferase reporter gene assay | 2014 | Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13 | SAR studies on curcumin's pro-inflammatory targets: discovery of prenylated pyrazolocurcuminoids as potent and selective novel inhibitors of 5-lipoxygenase. |
| AID243855 | Percent inhibition against Prostaglandin G/H synthase 2 from sheep placenta at 100 uM | 2005 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 15, Issue:7 | Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cyclooxygenase inhibitory and anti-inflammatory agents. |
| AID1511094 | Cytotoxicity against human WRO cells after 72 hrs in presence of curcumin by MTS assay relative to control | 2019 | European journal of medicinal chemistry, Oct-15, Volume: 180 | Recent advances of analogues of curcumin for treatment of cancer. |
| AID687446 | Inhibition of Albino Wistar rat CaMK2 in brain cytosolic fraction using GST-NR2A as substrate incubated for 1 min prior to substrate addition measured after 1 min | 2012 | Bioorganic & medicinal chemistry, Oct-15, Volume: 20, Issue:20 | Curcumin is an inhibitor of calcium/calmodulin dependent protein kinase II. |
| AID1155594 | Ratio of curcumin IC50 to compound IC50 for 5-LO-mediated 5-HETE formation in LPS-stimulated human monocytes preincubated for 15 mins before arachidonic acid substrate addition measured after 30 mins by UPLC-MS/MS analysis | 2014 | Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13 | SAR studies on curcumin's pro-inflammatory targets: discovery of prenylated pyrazolocurcuminoids as potent and selective novel inhibitors of 5-lipoxygenase. |
| AID418006 | Ratio of IC50 for human MCF10A cells to IC50 for human LNCAP cells | 2009 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7 | Structure-activity relationship studies of curcumin analogues. |
| AID1155574 | Inhibition of 5-LO in human neutrophils using arachidonic acid as substrate preincubated for 15 mins measured after 10 mins by HPLC analysis | 2014 | Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13 | SAR studies on curcumin's pro-inflammatory targets: discovery of prenylated pyrazolocurcuminoids as potent and selective novel inhibitors of 5-lipoxygenase. |
| AID630081 | Selectivity ratio of EC50 for PKCepsilon C1B subdomain to EC50 for PKCtheta C1B subdomain | 2011 | Bioorganic & medicinal chemistry, Nov-01, Volume: 19, Issue:21 | Binding of isoxazole and pyrazole derivatives of curcumin with the activator binding domain of novel protein kinase C. |
| AID687453 | Inhibition of alphaCaMK2 using GST-NR2A as substrate incubated for 1 min prior to substrate addition measured after 1 min | 2012 | Bioorganic & medicinal chemistry, Oct-15, Volume: 20, Issue:20 | Curcumin is an inhibitor of calcium/calmodulin dependent protein kinase II. |
| AID243850 | Percent inhibition against Prostaglandin G/H synthase 1 from ram seminal vesicles at 100 uM | 2005 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 15, Issue:7 | Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cyclooxygenase inhibitory and anti-inflammatory agents. |
| AID1175312 | Inhibition of amyloid beta-42 self-aggregation (unknown origin) at 25 uM after 20 hrs by ThT fluorescence assay | 2014 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 24, Issue:24 | Structure activity relationship study of curcumin analogues toward the amyloid-beta aggregation inhibitor. |
| AID1155595 | Ratio of curcumin IC50 to compound IC50 for 5-LO-mediated 5,12-DiHETE formation in LPS-stimulated human monocytes preincubated for 15 mins before arachidonic acid substrate addition measured after 30 mins by UPLC-MS/MS analysis | 2014 | Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13 | SAR studies on curcumin's pro-inflammatory targets: discovery of prenylated pyrazolocurcuminoids as potent and selective novel inhibitors of 5-lipoxygenase. |
| AID1155587 | Activation of Nrf2 transcriptional activity in human LNCaP cells after 6 hrs by luciferase reporter gene assay relative to tert-butylhydroquinone | 2014 | Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13 | SAR studies on curcumin's pro-inflammatory targets: discovery of prenylated pyrazolocurcuminoids as potent and selective novel inhibitors of 5-lipoxygenase. |
| AID418004 | Antiproliferative activity against human MCF10A cells after 72 hrs by MTT assay | 2009 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7 | Structure-activity relationship studies of curcumin analogues. |
| AID323181 | Antimalarial activity against chloroquine-resistant Plasmodium falciparum MP14 | 2008 | Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6 | Synthesis and exploration of novel curcumin analogues as anti-malarial agents. |
| AID1511096 | Cytotoxicity against human WRO cells at 5 umol/L after 72 hrs by MTS assay relative to control | 2019 | European journal of medicinal chemistry, Oct-15, Volume: 180 | Recent advances of analogues of curcumin for treatment of cancer. |
| AID630080 | Selectivity ratio of EC50 for PKCdelta C1B subdomain to EC50 for PKCtheta C1B subdomain | 2011 | Bioorganic & medicinal chemistry, Nov-01, Volume: 19, Issue:21 | Binding of isoxazole and pyrazole derivatives of curcumin with the activator binding domain of novel protein kinase C. |
| AID1155580 | Inhibition of purified ovine COX-1 assessed as residual activity by measuring formation of 12-HHT from arachidonic acid preincubated at 10 uM for 5 mins before substrate addition measured after 5 mins by HPLC analysis relative to control | 2014 | Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13 | SAR studies on curcumin's pro-inflammatory targets: discovery of prenylated pyrazolocurcuminoids as potent and selective novel inhibitors of 5-lipoxygenase. |
| AID1155588 | Cytotoxicity against human LNCAP cells assessed as cell viability after 24 hrs by MTT assay | 2014 | Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13 | SAR studies on curcumin's pro-inflammatory targets: discovery of prenylated pyrazolocurcuminoids as potent and selective novel inhibitors of 5-lipoxygenase. |
| AID1155584 | Inhibition of 15-LO in human neutrophils assessed as residual activity relative to control | 2014 | Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13 | SAR studies on curcumin's pro-inflammatory targets: discovery of prenylated pyrazolocurcuminoids as potent and selective novel inhibitors of 5-lipoxygenase. |
| AID1695732 | Inhibition of wild type alpha-synuclein aggregation (unknown origin) expressed in Escherichia coli BL21 cells incubated for 30 days by thioflavin T based fluorescence assay | 2019 | European journal of medicinal chemistry, Apr-01, Volume: 167 | Toward the discovery and development of effective modulators of α-synuclein amyloid aggregation. |
| AID1894194 | Inhibition of amyloid beta 38 secretion transfected in human H4 cells incubated for 20 to 24 hrs by LPECL assay | 2021 | European journal of medicinal chemistry, Mar-15, Volume: 214 | Amyloid-β and tau aggregation dual-inhibitors: A synthetic and structure-activity relationship focused review. |
| AID1155591 | Inhibition of 5-LO-mediated 5-HETE formation in LPS-stimulated human monocytes preincubated for 15 mins before arachidonic acid substrate addition measured after 30 mins by UPLC-MS/MS analysis | 2014 | Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13 | SAR studies on curcumin's pro-inflammatory targets: discovery of prenylated pyrazolocurcuminoids as potent and selective novel inhibitors of 5-lipoxygenase. |
| AID687454 | Inhibition of Albino Wistar rat CaMK2 in postsynaptic density fraction using GST-NR2A as substrate incubated for 1 min prior to substrate addition measured after 1 min in presence of EGTA | 2012 | Bioorganic & medicinal chemistry, Oct-15, Volume: 20, Issue:20 | Curcumin is an inhibitor of calcium/calmodulin dependent protein kinase II. |
| AID1155589 | Cytotoxicity against human PBMCs assessed as cell viability after 24 hrs by MTT assay | 2014 | Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13 | SAR studies on curcumin's pro-inflammatory targets: discovery of prenylated pyrazolocurcuminoids as potent and selective novel inhibitors of 5-lipoxygenase. |
| AID1894193 | Inhibition of amyloid beta 42 transfected in human H4 cells incubated for 20 to 24 hrs by LPECL assay | 2021 | European journal of medicinal chemistry, Mar-15, Volume: 214 | Amyloid-β and tau aggregation dual-inhibitors: A synthetic and structure-activity relationship focused review. |
| AID1511095 | Cytotoxicity against human MCF7/R cells at 5 umol/L after 72 hrs by MTS assay relative to control | 2019 | European journal of medicinal chemistry, Oct-15, Volume: 180 | Recent advances of analogues of curcumin for treatment of cancer. |
| AID418008 | Ratio of IC50 for human MCF10A cells to IC50 for human MDA-MB-231 cells | 2009 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7 | Structure-activity relationship studies of curcumin analogues. |
| AID687395 | Inhibition of Albino Wistar rat CaMK2 in postsynaptic density fraction using GST-NR2A as substrate incubated for 1 min prior to substrate addition measured after 1 min | 2012 | Bioorganic & medicinal chemistry, Oct-15, Volume: 20, Issue:20 | Curcumin is an inhibitor of calcium/calmodulin dependent protein kinase II. |
| AID1155581 | Inhibition of purified human COX-2 assessed as residual activity by measuring formation of 12-HHT from arachidonic acid preincubated at 10 uM for 5 mins before substrate addition measured after 5 mins by HPLC analysis relative to control | 2014 | Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13 | SAR studies on curcumin's pro-inflammatory targets: discovery of prenylated pyrazolocurcuminoids as potent and selective novel inhibitors of 5-lipoxygenase. |
| AID1155585 | Inhibition of TNFalpha-induced NF-kappaB transcriptional activity in human 5.1 cells after 6 hrs | 2014 | Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13 | SAR studies on curcumin's pro-inflammatory targets: discovery of prenylated pyrazolocurcuminoids as potent and selective novel inhibitors of 5-lipoxygenase. |
| AID515080 | Antimycobacterial activity against Mycobacterium tuberculosis H37Ra after 24 hrs by microtiter alamar blue assay | 2010 | European journal of medicinal chemistry, Oct, Volume: 45, Issue:10 | Isoxazole analogs of curcuminoids with highly potent multidrug-resistant antimycobacterial activity. |
| AID1155573 | Inhibition of human recombinant 5-LO expressed in Escherichia coli Bl21 (DE3) using arachidonic acid as substrate preincubated for 10 mins measured after 10 mins by RP-HPLC analysis | 2014 | Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13 | SAR studies on curcumin's pro-inflammatory targets: discovery of prenylated pyrazolocurcuminoids as potent and selective novel inhibitors of 5-lipoxygenase. |
| AID1398099 | Disruption of recombinant human amyloid beta (1 to 40) fibrils at 10 uM after 24 hrs by ThT fluorescence assay relative to control | 2018 | Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14 | Curcumin derivatives and Aβ-fibrillar aggregates: An interactions' study for diagnostic/therapeutic purposes in neurodegenerative diseases. |
| AID1155577 | Aqueous stability of the compound in at 2 uM in 10 mM aqueous ammonium bicarbonate at pH 7.9 assessed as formation of trans-6-(4'-hydroxy-3'-methoxyphenyl)-2,4-dioxo-5-hexenal measured as residual amount of compound by reversed phase liquid chromatography | 2014 | Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13 | SAR studies on curcumin's pro-inflammatory targets: discovery of prenylated pyrazolocurcuminoids as potent and selective novel inhibitors of 5-lipoxygenase. |
| AID687450 | Inhibition of autophosphorylated alphaCaMK2 using GST-NR2A as substrate incubated for 1 min prior to substrate addition measured after 1 min in presence of EGTA | 2012 | Bioorganic & medicinal chemistry, Oct-15, Volume: 20, Issue:20 | Curcumin is an inhibitor of calcium/calmodulin dependent protein kinase II. |
| AID1894197 | Inhibition of tau (unknown origin) transfected in human H4 cells incubated for 20 to 24 hrs by LPECL assay | 2021 | European journal of medicinal chemistry, Mar-15, Volume: 214 | Amyloid-β and tau aggregation dual-inhibitors: A synthetic and structure-activity relationship focused review. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (31.03) | 29.6817 |
| 2010's | 15 (51.72) | 24.3611 |
| 2020's | 5 (17.24) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 3 (10.34%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 26 (89.66%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||